Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Gains from Investment Securities: 2014-2025

Historic Gains from Investment Securities for KalVista Pharmaceuticals (KALV) over the last 2 years, with Apr 2025 value amounting to $369,000.

  • KalVista Pharmaceuticals' Gains from Investment Securities rose 89.23% to $369,000 in Q2 2025 from the same period last year, while for Apr 2025 it was $1.5 million, marking a year-over-year increase of 15.47%. This contributed to the annual value of $1.6 million for FY2025, which is 17.81% up from last year.
  • KalVista Pharmaceuticals' Gains from Investment Securities amounted to $369,000 in Q2 2025, which was down 43.14% from $649,000 recorded in Q4 2024.
  • KalVista Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $649,000 during Q4 2024, with a 5-year trough of $195,000 in Q2 2024.
  • In the last 3 years, KalVista Pharmaceuticals' Gains from Investment Securities had a median value of $317,000 in 2024 and averaged $380,000.
  • Data for KalVista Pharmaceuticals' Gains from Investment Securities shows a peak YoY surged of 89.23% (in 2025) over the last 5 years.
  • KalVista Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $595,000 in 2023, then rose by 9.08% to $649,000 in 2024, then soared by 89.23% to $369,000 in 2025.
  • Its last three reported values are $369,000 in Q2 2025, $649,000 for Q4 2024, and $317,000 during Q3 2024.